Mateon Therapeutics (NASDAQ: MATN) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Mateon Therapeutics and Soligenix, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mateon Therapeutics 0 1 3 0 2.75
Soligenix 0 0 3 0 3.00

Mateon Therapeutics presently has a consensus price target of $2.00, indicating a potential upside of 341.99%. Soligenix has a consensus price target of $7.33, indicating a potential upside of 245.91%. Given Mateon Therapeutics’ higher probable upside, research analysts clearly believe Mateon Therapeutics is more favorable than Soligenix.

Earnings and Valuation

This table compares Mateon Therapeutics and Soligenix’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Mateon Therapeutics N/A N/A -$14.59 million ($0.54) -0.84
Soligenix $6.98 million 1.74 -$6.76 million ($1.36) -1.56

Soligenix has higher revenue and earnings than Mateon Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

8.6% of Mateon Therapeutics shares are owned by institutional investors. Comparatively, 2.0% of Soligenix shares are owned by institutional investors. 2.3% of Mateon Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Mateon Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.31, suggesting that its stock price is 131% more volatile than the S&P 500.

Profitability

This table compares Mateon Therapeutics and Soligenix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mateon Therapeutics N/A -224.38% -186.53%
Soligenix -86.15% -129.88% -74.33%

Summary

Soligenix beats Mateon Therapeutics on 7 of the 11 factors compared between the two stocks.

About Mateon Therapeutics

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

About Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Stock Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related stocks with our FREE daily email newsletter.